Experienced in IgG4-Related Disease

Dr. Lorinda S. Chung

Rheumatology
300 Pasteur Dr, 
Stanford, CA 
Offers Telehealth
Experienced in IgG4-Related Disease
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lorinda Chung is a Rheumatologist in Stanford, California. Dr. Chung is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Dermatomyositis, and Polymyositis.

Her clinical research consists of co-authoring 181 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
Use of FLIP Topography to Evaluate Esophageal Symptoms in Patients With Scleroderma
Use of FLIP Topography to Evaluate Esophageal Symptoms in Patients With Scleroderma
Enrollment Status: Withdrawn
Publish Date: January 20, 2021
Intervention Type: Device, Procedure
Study Phase: Not Applicable
View 6 Less Clinical Trials

181 Total Publications

Reply to Letter to the Editor: Validation of Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease in Systemic Sclerosis and Inflammatory Myopathy.
Reply to Letter to the Editor: Validation of Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease in Systemic Sclerosis and Inflammatory Myopathy.
Journal: Arthritis care & research
Published: June 23, 2025
Similar Doctors
Distinguished in IgG4-Related Disease
Dr. Matthew C. Baker
Rheumatology
Distinguished in IgG4-Related Disease
Dr. Matthew C. Baker
Rheumatology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Baker is a Rheumatologist in Stanford, California. Dr. Baker is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Sarcoidosis, IgG4-Related Disease, Neurosarcoidosis, Dermatomyositis, and Vagotomy.

Advanced in IgG4-Related Disease
Dr. Andrew J. Gross
Rheumatology
Advanced in IgG4-Related Disease
Dr. Andrew J. Gross
Rheumatology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (27.6 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Gross is a Rheumatologist in San Francisco, California. Dr. Gross is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Rheumatoid Arthritis (RA), Scleroderma, Systemic Sclerosis (SSc), and Scleroma.

Advanced in IgG4-Related Disease
Dr. Yashaar Chaichian
Rheumatology
Advanced in IgG4-Related Disease
Dr. Yashaar Chaichian
Rheumatology

Stanford Health Care

420 Broadway St, 
Redwood City, CA 
 (3.9 miles away)
650-723-4000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yashaar Chaichian is a Rheumatologist in Redwood City, California. Dr. Chaichian has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, MASS Phenotype, and Mixed Connective Tissue Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chung's expertise for a condition
ConditionClose
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile